BACKGROUND AND PURPOSE: Human albumin has been shown to exert neuroprotective effects in animal models of cerebral ischemia and humans with various intracranial pathologies. We investigated the safety and tolerability of 25% human albumin in patients with subarachnoid hemorrhage. METHODS: The Albumin in Subarachnoid Hemorrhage (ALISAH) Pilot Clinical Trial was an open-label, dose-escalation study. We intended to study 4 different dosages of albumin of increasing magnitude (0.625 g/kg: Tier 1; 1.25 g/kg: Tier 2; 1.875 g/kg: Tier 3; and 2.5 g/kg: Tier 4). Each dosage was to be given to 20 adult patients. Treatment was administered daily for 7 days. We investigated the maximum tolerated dose of albumin based on the rate of severe-to-life-threatening heart failure and anaphylactic reaction and functional outcome at 3 months. RESULTS: We treated 47 adult subjects: 20 in Tier 1; 20 in Tier 2; and 7 in Tier 3. We found that doses ranging up to 1.25 g/kg/day×7 days were tolerated by patients without major dose-limiting complications. We also found that outcomes trended toward better responses in those subjects enrolled in Tier 2 compared with Tier 1 (OR, 3.0513; CI, 0.6586-14.1367) and with the International Intraoperative Hypothermia for Aneurysm Surgery Trial cohort (OR, 3.1462; CI, 0.9158-10.8089). CONCLUSIONS:Albumin in doses ranging up to 1.25 g/kg/day×7 days was tolerated by patients with subarachnoid hemorrhage without major complications and may be neuroprotective. Based on these results, planning of the ALISAH II, a Phase III, randomized, placebo-controlled trial to test the efficacy of albumin, is underway. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00283400.
RCT Entities:
BACKGROUND AND PURPOSE:Humanalbumin has been shown to exert neuroprotective effects in animal models of cerebral ischemia and humans with various intracranial pathologies. We investigated the safety and tolerability of 25% humanalbumin in patients with subarachnoid hemorrhage. METHODS: The Albumin in Subarachnoid Hemorrhage (ALISAH) Pilot Clinical Trial was an open-label, dose-escalation study. We intended to study 4 different dosages of albumin of increasing magnitude (0.625 g/kg: Tier 1; 1.25 g/kg: Tier 2; 1.875 g/kg: Tier 3; and 2.5 g/kg: Tier 4). Each dosage was to be given to 20 adult patients. Treatment was administered daily for 7 days. We investigated the maximum tolerated dose of albumin based on the rate of severe-to-life-threatening heart failure and anaphylactic reaction and functional outcome at 3 months. RESULTS: We treated 47 adult subjects: 20 in Tier 1; 20 in Tier 2; and 7 in Tier 3. We found that doses ranging up to 1.25 g/kg/day×7 days were tolerated by patients without major dose-limiting complications. We also found that outcomes trended toward better responses in those subjects enrolled in Tier 2 compared with Tier 1 (OR, 3.0513; CI, 0.6586-14.1367) and with the International Intraoperative Hypothermia for Aneurysm Surgery Trial cohort (OR, 3.1462; CI, 0.9158-10.8089). CONCLUSIONS:Albumin in doses ranging up to 1.25 g/kg/day×7 days was tolerated by patients with subarachnoid hemorrhage without major complications and may be neuroprotective. Based on these results, planning of the ALISAH II, a Phase III, randomized, placebo-controlled trial to test the efficacy of albumin, is underway. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00283400.
Authors: S Mehta; G D Jay; R H Woolard; R A Hipona; E M Connolly; D M Cimini; J H Drinkwine; N S Hill Journal: Crit Care Med Date: 1997-04 Impact factor: 7.598
Authors: H Zoellner; M Höfler; R Beckmann; P Hufnagl; E Vanyek; E Bielek; J Wojta; A Fabry; S Lockie; B R Binder Journal: J Cell Sci Date: 1996-10 Impact factor: 5.285
Authors: Réza Behrouz; Daniel A Godoy; Christopher Hans Topel; Lee A Birnbaum; Jean-Louis Caron; Ramesh Grandhi; Jeremiah N Johnson; Vivek Misra; Ali Seifi; Kathleen Urbansky; Mario Di Napoli Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210
Authors: Martin N Stienen; Johanna M Visser-Meily; Tom A Schweizer; Daniel Hänggi; R Loch Macdonald; Mervyn D I Vergouwen Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210
Authors: Rakesh Khatri; Mohammad Rauf Afzal; Gustavo J Rodriguez; Alberto Maud; Muhammad Shah Miran; Mohtashim Arbaab Qureshi; Salvador Cruz-Flores; Adnan I Qureshi Journal: Neurocrit Care Date: 2018-02 Impact factor: 3.210
Authors: Jose I Suarez; Renee H Martin; Eusebia Calvillo; David Zygun; Oliver Flower; George K Wong; Eric M Bershad; Chethan P Venkatasubba Rao; Alexandros Georgiadis; Draga Jichici; Peter D Leroux Journal: Neurocrit Care Date: 2014-04 Impact factor: 3.210
Authors: Airton Leonardo de Oliveira Manoel; Mathieu van der Jagt; Sepideh Amin-Hanjani; Nicholas C Bambakidis; Gretchen M Brophy; Ketan Bulsara; Jan Claassen; E Sander Connolly; S Alan Hoffer; Brian L Hoh; Robert G Holloway; Adam G Kelly; Stephan A Mayer; Peter Nakaji; Alejandro A Rabinstein; Peter Vajkoczy; Mervyn D I Vergouwen; Henry Woo; Gregory J Zipfel; Jose I Suarez Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210